Your browser doesn't support javascript.
loading
Impaired glymphatic function and clearance of tau in an Alzheimer's disease model.
Harrison, Ian F; Ismail, Ozama; Machhada, Asif; Colgan, Niall; Ohene, Yolanda; Nahavandi, Payam; Ahmed, Zeshan; Fisher, Alice; Meftah, Soraya; Murray, Tracey K; Ottersen, Ole P; Nagelhus, Erlend A; O'Neill, Michael J; Wells, Jack A; Lythgoe, Mark F.
Afiliação
  • Harrison IF; UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK.
  • Ismail O; UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK.
  • Machhada A; UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK.
  • Colgan N; Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK.
  • Ohene Y; UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK.
  • Nahavandi P; School of Physics, National University of Ireland Galway, Ireland.
  • Ahmed Z; UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK.
  • Fisher A; UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK.
  • Meftah S; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK.
  • Murray TK; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK.
  • Ottersen OP; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK.
  • Nagelhus EA; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK.
  • O'Neill MJ; Office of the President, Karolinska Institutet, Stockholm, Sweden.
  • Wells JA; Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
  • Lythgoe MF; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK.
Brain ; 143(8): 2576-2593, 2020 08 01.
Article em En | MEDLINE | ID: mdl-32705145
ABSTRACT
The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-ß and tau, which accumulate in the brain in Alzheimer's disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer's disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer's disease, and possibly other neurodegenerative diseases alike.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Proteínas tau / Aquaporina 4 / Doença de Alzheimer / Sistema Glinfático Limite: Animals Idioma: En Revista: Brain Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Proteínas tau / Aquaporina 4 / Doença de Alzheimer / Sistema Glinfático Limite: Animals Idioma: En Revista: Brain Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido